Latest Scleroderma Stories
Patient biopsies reveal potential new target for therapy A genetic pathway previously known for its role in embryonic development and cancer has been identified as a target for systemic sclerosis, or scleroderma, therapy. The finding, discovered by a cross-disciplinary team led by John Varga, MD, John and Nancy Hughes Distinguished Professor of Rheumatology at Northwestern University Feinberg School of Medicine, was recently published in the journal Arthritis & Rheumatism. "We...
Funds Three Key Scleroderma Research Projects DANVERS, Mass., Feb. 29, 2012 /PRNewswire-USNewswire/ -- The U.S. Department of Defense announced that it will fund three important scleroderma research projects as part of its Fiscal Year 2011 Peer Reviewed Medical Research Program. The following investigators have been awarded grant funding: Sandeep Agarwal, M.D., Ph.D., assistant professor of medicine, Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston. Robert...
"Exploring the Scleroderma Research Toolbox": a free informational Webinar from the Scleroderma Research Foundation on February 10, 2012. San Francisco, CA (PRWEB) February 03, 2012 The Scleroderma Research Foundation (SRF) is presenting the next webinar in their series for people living with scleroderma and others directly or indirectly affected by the disease. The free Webinar will educate viewers on the tools used by investigators to propel research forward as well as what...
National Congressional Call-in Day Wednesday, Feb. 8 DANVERS, Mass., Feb. 3, 2012 /PRNewswire-USNewswire/ -- The Scleroderma Foundation unveiled a unique awareness campaign today with the help of OrgSpring, an online technology firm that helps nonprofit organizations build and maintain relationships with supporters. Through the campaign, people living with scleroderma, their family members, friends and others are urged to change their Facebook Profile Timeline cover images in...
Eight Researchers Receive Grant Funding DANVERS, Mass., Feb. 1, 2012 /PRNewswire-USNewswire/ -- The Scleroderma Foundation's commitment to fund research remains strong despite the continued difficult economic climate. At a time when many organizations and government agencies are cutting back on vital research funding, the Board of Directors unanimously voted to increase the Foundation's research funding from the budgeted $1 million to $1.2 million for 2012. The Foundation...
Effort Supports the Coalition for Pulmonary Fibrosis POTOMAC FALLS, Va., Jan. 26, 2012 /PRNewswire-USNewswire/ -- Catherine Goodrum has been afraid of being in open water most of her life. In an effort to overcome her fear, Goodrum joined a Total Immersion(TM) Women's Swim Camp in St. John, U.S. Virgin lslands and turned the experience into a tribute to her father who died from Pulmonary Fibrosis (PF) in 2009. Goodrum swam a total of nine miles during the camp and used her...
Promo Pays Tribute to Mary Kay Director Lost to Pulmonary Fibrosis CULVER CITY, Calif., Dec. 22, 2011 /PRNewswire-USNewswire/ -- The Coalition for Pulmonary Fibrosis (CPF) announced today the launch of the first campaign to raise funds for Pulmonary Fibrosis (PF) while paying tribute to a Mary Kay independent sales director who lost her fight to PF at the age of 45. The "Lips for a Cure" campaign kicks off today and runs through February 29, 2012. (To view ad, visit:...
Special Guests Include Seth Meyers, Colin Quinn, Jeffrey Ross and Others NEW YORK, Nov. 1, 2011 /PRNewswire-USNewswire/ -- Bob Saget will host Cool Comedy - Hot Cuisine, the Scleroderma Research Foundation's (SRF) signature benefit, Monday, November 7 at Carolines on Broadway. Saget, an SRF Board Member who lost his sister to scleroderma, will be joined in the fundraising effort by comedians Seth Meyers (Saturday Night Live), Colin Quinn (Saturday Night Live) and Jeffrey Ross (New York...
EASTBOURNE, England, October 10, 2011 /PRNewswire/ -- Daval International today announced positive results from its Double-Blind Placebo-Controlled Phase II Clinical Study evaluating the safety and tolerability of AIMSPRO given as a monotherapy to patients with Late Stage Established Diffuse Cutaneous Systemic Sclerosis (diffuse scleroderma). The study evaluated the effects of 4.5mg/ml doses of AIMSPRO, administered subcutaneously, twice weekly for 26 weeks compared with...
Progress and Promise in Clinical Research Premieres October 20, 2011 SAN FRANCISCO, Sept. 14, 2011 /PRNewswire-USNewswire/ -- The Scleroderma Research Foundation (SRF) announces the first in a series of free informational Webinars for people living with scleroderma and others directly or indirectly affected by the disease. The first Webinar will highlight new clinical trials and results from recent studies. "Scleroderma" literally means "hard skin," but oftentimes the illness affects...
